BloggingStocks (Free subscription) | 12/03/2009
Filed under: Newsletters , Amgen Inc (AMGN) , ETF Investing , Commodities , Oil , Agriculture , Stocks to Buy "Nothing has changed to unseat this liquidity-driven rally," says options expert Larry McMillan . In his trading service, The Daily Strategist , he eyes the technical side of the market and some new trading ideas. McMillan explains, "Following a test of the uptrend line around...
BloggingStocks (Free subscription) | 10/19/2009
Filed under: Sprint Nextel Corp (S) , CIT Group (CIT) , Federal Natl Mtge (FNM) , Amgen Inc (AMGN) Despite a cautious report from home builders and despite a low volume day, today marked a clear win for the S&P 5000 and for the DJIA. The S&P broke through 1,100 and the DJIA broke through 11,000. We also had two mergers this morning, and while small they are signs that companies are willing...
BloggingStocks (Free subscription) | 10/14/2009
Filed under: Amgen Inc (AMGN) Amgen (NASDAQ: AMGN ) closed at $59.27. AMGN is scheduled to report Q3 EPS on October 21. AMGN's Dmab PDUFA is expected on October 19th. AMGN November option implied volatility is at 35, January is at 34; verses its six-month average of 37, according to Track Data, suggesting decreasing price movement. CBOE streetTracks Gold Shares (NYYSE: GLD ) is recently down 13c to...
EmailWire.Com (Free subscription) | 10/01/2009
(EMAILWIRE.COM, October 01, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biopharmaceutical company XOMA Ltd. (Nasdaq: XOMA). The investment report on XOMA Ltd. (Nasdaq: XOMA) should be of particular interest to other biopharmaceutical companies: Amgen Inc....
EmailWire.Com (Free subscription) | 09/17/2009
(EMAILWIRE.COM, September 17, 2009 ) DALLAS, Texas - InvestorSoup.com announces an investment report featuring JAZZ Pharmaceuticals Inc. (JAZZ). The investment report on JAZZ Pharmaceuticals Inc. (JAZZ) should be of particular interest other pharmaceutical and biotechnology companies: Amgen Inc....
Buffett Junior - Investment Blog (Free subscription) | 08/20/2009
Filed under: Netflix, Inc. (NFLX), Amer Intl Group (AIG), Options Netflix (NYSE: NFLX) closed at$44.87. NFLX is presenting at the Citi Tech Conference on September 9. NFLX September option implied volatility is at 42, December is at 47; verses its 26-week average of 52 according to Track Data, suggesting decreasing price movement. American International Group (NYSE: [...] Related posts: Options Update:...
Radon Mitigation Pittsburgh (Free subscription) | 08/18/2009
(EMAILWIRE.COM, August 18, 2009 ) Del Mar, California WallStreetStockReview.com (http://www.WallStreetStockReview.com) Reports on Stocks to Watch: Mundus Group, Inc. (Other OTC: MNDP), Novogen Limited(Nasdaq: NVGN),Targacept, Inc.(Nasdaq: TRGT),Internet Initiative Japan, Inc.(Nasdaq: IIJI),Amgen Inc.(Nasdaq: AMGN) Featured Stock: Mundus Group, Inc. (Other OTC: MNDP) http://www.WallStreetStockReview.com...
BloggingStocks (Free subscription) | 08/15/2009
Filed under: Amgen Inc (AMGN) , Comfort Zone Investing Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money. Cures for all types of cancers always seem imminent with promising (there's that word again) results from mice or small control groups. Phase I testing is completed and all kinds of good stuff seems possible. Then something usually...
L. A. Times Dodgers Blog (Free subscription) | 08/13/2009
The experimental drug benefits patients being treated for osteoporosis, advisory panel says. But it does not recommend it for preventive use. The FDA is due to decide in October. Biotech leader Amgen Inc. cleared a major hurdle today in its push to win approval for its experimental osteoporosis drug from the Food and Drug Administration.
Miami Herald (Free subscription) | 08/13/2009
Federal health experts say a drug from Amgen Inc. benefits patients with osteoporosis, but its use should be limited because of long-term safety questions.
San Diego Union (Free subscription) | 08/13/2009
Federal health experts say a drug from Amgen Inc. benefits patients with osteoporosis, but its use should be limited because of long-term safety questions.
PR News Wire (Free subscription) | 08/13/2009
Serving a rapidly growing segment of the investment community, the Options News Network is the first media outlet focused exclusively on providing top quality daily options news and entertainment, options education, options trading ideas, options strategies, and expert commentary on the options market, targeting options traders of all skill and experience levels as well as stock investors thinking...
Market Watch (Free subscription) | 08/13/2009
BOSTON (MarketWatch) -- Drug stocks were a bit lower in early trading Thursday as shares of Amgen Inc. slipped ahead of a scheduled FDA advisory panel meeting that will review its new bone-loss drug candidate denosumab. The NYSE Arca Pharmaceutical Index eased 0.4% to 277.62 while the NYSE Arca Biotechnology Index was down nominally at 874.97. Shares of Amgen dipped 1% to $61.90. Market Pulse Stories...
Medical News Today (Free subscription) | 08/12/2009
Amgen Inc. (Nasdaq: AMGN) announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss.
San Fransisco Chronicle (Free subscription) | 08/11/2009
Federal health officials are questioning increased infection rates and tumors seen with an osteoporosis drug from Amgen that analysts say is key to the company's growth. The Food and Drug Administration said Tuesday that patients taking Amgen Inc.'s denosumab... Sponsored Topics: Amgen - US Food and Drug Administration - Osteoporosis - Food and Drug Administration - Osteoporosis drug market
Videos